A study published today in the Journal of National Cancer Institute (JNCI) by ICREA researcher Roger Gomis may be key to the early detection of patients at risk of developing metastasis to the bone
This new knowledge may accelerate the development of the first preventive treatment of bone metastasis
Inbiomotion, an IRB Barcelona spin off company and financed with venture investors Ysios Capital, has already begun clinical trials
Physicians currently have no tools to help them detect which breast cancer patients will suffer metastasis to the bone, a process that occurs in 15-20% of cases. A study led by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) and published today in JNCI has uncovered a gene that allows breast cancer cells to invade bones and create new tumours, or to metastasize. This discovery has been patented and transferred to Inbiomotion, a spin off from the IRB Barcelona and ICREA, founded at the end of 2010. Inbiomotion, led by the venture investor Ysios Capital, has developed the technology necessary to validate the marker in clinical trials, which are already underway.
Bone metastasis is the only type of metastasis that can be controlled, but not cured, by drugs. Treatment is only given once the metastasis has been identified, which is normally too late. Preliminary studies indicate that the same drugs used to treat metastasis could also be used to prevent it, and identifying those patients at risk of developing bone metastasis is therefore very important. “This is where the discovery made at IRB Barcelona could be of great use to clinicians and would avoid unnecessary treatment of patients who are not at risk," suggests Gomis.
About one million new cases of breast cancer are diagnosed each year. Preventive treatment for bone metastasis can have unwanted side effects and comes at a high cost, making a broad administration of the drugs an unviable option, even less so considering only 15-20% of patients are likely to develop metastasis over time. "In order to implement a well-designed clinical trial, we first need to know which patients may benefit and which ones will not. Our discovery offers a way to distinguish that wasn't possible before," confirms Gomis.
Conducting metastasis to the bone
Experiments in the Growth Control and Cancer Metastasis Laboratory at the Institute for Research in Biomedicine (IRB Barcelona) have focussed on the analysis of estrogen-receptor-positive breast tumours since they specifically tend to metastasize to the bone, and represent 80% of all breast cancers. The results indicate that the gene MAF triggers a set of functions in the cell that allow metastasis to take place.
The researchers analyzed more than 900 clinical samples of primary breast tumours. In tumours in which the MAF gene is altered, the risk of metastasis to the bone is 14 times higher than in those in which it is unaltered. “This gene reliably predicts metastasis to the bone. Studying whether it is highly expressed in breast cancer patients to determine whether this also happens in a clinical setting is an important next step. It could improve the quality of life of these patients and the way clinicians manage their cancer. And this is exactly what we are doing”, explains the researcher.
Clinical trials underway
The study, published today in the open access Journal of National Cancer Institute (JNCI), one of the most-read specialized oncology journals, is an ongoing technology transfer project at IRB Barcelona. The discovery has led to the creation of the company Inbiomotion, founded by Gomis and in which ICREA also participates. The spin off received funding in 2012 from the venture capital company Ysios Capital and the Vila Casas Foundation to develop the tools necessary for the clinical trials. Inbiomotion has now delivered the technology and has begun to validate the marker in clinical trials in 3,300 patients.
The first two authors of the study published today are PhD students, Milica Pavlovic, recipient of a “la Caixa” Foundation fellowship, and Anna Arnal-Estapé, both from the Gomis laboratory. The research was conducted in collaboration with several clinical centers based in Catalonia (Hospital del Mar with Dr. Joan Albanell and the Hospital Clínic de Barcelona with Dr. Aleix Prat), in the rest of Spain (Hospital Clínico de Valencia with Dr. Ana Lluch and the Fundación Jiménez Díaz with Dr. Federico Rojo), as well as with international centers (Sheffield Cancer Research Center with Prof. Robert Coleman, a world expert in bone metastasis).
Dr Roger Gomis’ laboratory is supported by the BBVA Foundation, the Spanish Ministry of Economy and Competitiveness and the Government of Catalonia.
Reference article:
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Milica Pavlovic, Anna Arnal-Estapé, Federico Rojo, Anna Bellmunt, Maria Tarragona, Marc Guiu, Evarist Planet, Xabier Garcia-Albéniz, Mónica Morales, Jelena Urosevic, Sylwia Gawrzak, Ana Rovira, Aleix Prat, Lara Nonell, Ana Lluch, Joël Jean-Mairet, Robert Coleman, Joan Albanell, Roger R. Gomis
JNCI J Natl Cancer Inst (2015) 107(12): djv256 doi:10.1093/jnci/djv256
The economics newspaper Expansión Catalunya has echoed the forthcoming publication of the results of a clinical assay of the MAF-Test, a diagnostic test for breast cancer patients developed by Inbiomotion, a spin-off from IRB Barcelona set up in 2010 by the researcher Roger Gomis. The results are expected to be out in November.
Israel Ramos is a drug discovery professional specialised in in vitro assay development support to research programs and compound characterisation. With his more than 15 years of experience in the pharmaceutical industry, he is currently working at the at IRB Barcelona Innovation department as Technology Transfer Consultant. Israel provides support to IRB Barcelona researchers by giving advice about the applicability of potential drug candidates based on IRB Barcelona discoveries.
It is estimated that one in four people will require brain treatment at some point. While there are drug candidates for most diseases of the brain, the blood-brain barrier (BBB) poses an impassable obstacle for most of these compounds and a bottleneck for the delivery of drugs that could cure these patients.
